Get the Stockscreener App
12.48
0.24%
0.03
Cadrenal Therapeutics Inc stock is traded at $12.48, with a volume of 18,913.
It is up +0.24% in the last 24 hours and up +15.45% over the past month.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$12.45
Open:
$12.53
24h Volume:
18,913
Relative Volume:
0.67
Market Cap:
$25.54M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-40.26
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
-1.58%
1M Performance:
+15.45%
6M Performance:
-37.25%
1Y Performance:
+82.19%
1-Day Range:
$12.25
$12.86
1-Week Range:
$12.25
$13.93
52-Week Range:
$6.8205
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
12.48 | 26.71M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Is KALA trending in predictive chart modelsPortfolio Growth Summary & Fast Gaining Stock Reports - Newser
Cadrenal Therapeutics Inc. Included in Top Momentum Scan2025 Year in Review & AI Based Buy and Sell Signals - mustnews.co.kr
Strategies to average down on Cadrenal Therapeutics Inc.July 2025 EndofMonth & Reliable Trade Execution Plans - Newser
Short interest data insights for Cadrenal Therapeutics Inc.Trade Analysis Summary & Daily Profit Focused Stock Screening - Newser
News impact scoring models applied to Cadrenal Therapeutics Inc.2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
Is it time to cut losses on MACIWJuly 2025 Gainers & Long-Term Safe Investment Ideas - Newser
Trend analysis for Cadrenal Therapeutics Inc. this weekJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
Is it too late to sell Medicus Pharma Ltd. Equity WarrantJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - Newser
Regression Model Predicts Rangebound Movement in Cadrenal Therapeutics Inc.2025 Key Lessons & Weekly Breakout Stock Alerts - Newser
Will Chenghe Acquisition II Co. bounce back from current support2025 Biggest Moves & Precise Buy Zone Identification - Newser
Analyzing Cadrenal Therapeutics Inc. with risk reward ratio chartsTrend Reversal & Entry and Exit Point Strategies - Newser
Published on: 2025-08-19 23:44:12 - Newser
Best data tools to analyze Cadrenal Therapeutics Inc. stockQuarterly Growth Report & Technical Buy Zone Confirmations - Newser
Combining price and volume data for Cadrenal Therapeutics Inc.Share Buyback & Stock Portfolio Risk Management - Newser
Generac Holdings Inc. recovery potential after sell offMarket Performance Summary & Technical Confirmation Trade Alerts - Newser
Cadrenal Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Sector Moves & Safe Swing Trade Setups - Newser
Technical signs of recovery in SpringWorks Therapeutics Inc.2025 Macro Impact & Technical Confirmation Alerts - Newser
Live market analysis of QLGNGlobal Markets & Weekly Momentum Stock Picks - Newser
RF.PRE Added to High Probability Setup ListJuly 2025 Spike Watch & Reliable Breakout Stock Forecasts - Newser
Using data tools to time your Cadrenal Therapeutics Inc. exitPortfolio Return Report & Weekly Breakout Stock Alerts - Newser
Using economic indicators to assess Cadrenal Therapeutics Inc. potentialJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Live Scanner Shows Breakout on Cadrenal Therapeutics Inc.2025 Technical Overview & AI Forecast for Swing Trade Picks - 선데이타임즈
Can machine learning forecast Cadrenal Therapeutics Inc. recoveryJuly 2025 Breakouts & Daily Volume Surge Signals - Newser
Published on: 2025-08-17 05:10:11 - Newser
Is Skyline Builders Group Holding Limited stock reversal real or fakeInsider Selling & Weekly High Return Stock Opportunities - Newser
Using data models to predict Cadrenal Therapeutics Inc. stock movementJuly 2025 Market Mood & Advanced Technical Analysis Signals - Newser
Is it time to cut losses on Relmada Therapeutics Inc.Long Setup & Real-Time Stock Entry Alerts - Newser
How sentiment analysis helps forecast RPIDWall Street Watch & Low Risk Entry Point Guides - Newser
Investors Hope for Bounce in Cadrenal Therapeutics Inc. After SelloffMarket Sentiment Report & AI Powered Trade Plan Recommendations - newsyoung.net
Earnings visualization tools for Cadrenal Therapeutics Inc.Earnings Recap Summary & Entry Point Confirmation Signals - Newser
Custom strategy builders for tracking Cadrenal Therapeutics Inc.Market Risk Analysis & Growth Focused Stock Reports - Newser
Real time breakdown of Cadrenal Therapeutics Inc. stock performanceGap Down & Weekly Setup with High ROI Potential - Newser
Is Cadrenal Therapeutics Inc. stock a good pick for beginnersPortfolio Growth Summary & Free Accurate Trade Setup Notifications - newsyoung.net
Q3 EPS Estimate for Cadrenal Therapeutics Lifted by Analyst - Defense World
How TOYO stock performs during market volatility2025 Fundamental Recap & Verified Momentum Stock Alerts - thegnnews.com
Is It Too Late to Sell Cadrenal Therapeutics Inc.Stock Surge & Weekly High Return Stock Forecasts - classian.co.kr
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
Q1 Earnings Forecast for CVKD Issued By Noble Financial - Defense World
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):